Genetics.
- Published in:
- 2010
- Publication type:
- Opinion
Works matching IS 20412177 AND DT 2010 AND VI 2 AND IP 3
Results: 25
1
2
Outcome Measures.
- Published in:
- 2010
- Publication type:
- Opinion
3
Cortical Reorganization.
- Published in:
- 2010
- Publication type:
- Opinion
4
Disease Presentation.
- Published in:
- 2010
- Publication type:
- Opinion
5
Neuromyelitis Optica.
- Published in:
- 2010
- Publication type:
- Opinion
6
Prognosis.
- Published in:
- 2010
- Publication type:
- Opinion
7
Pathogenesis.
- Published in:
- 2010
- Publication type:
- Opinion
8
Etiology.
- Published in:
- 2010
- Publication type:
- Opinion
9
Frontal networks play a role in fatigue perception in multiple sclerosis.
- Published in:
- 2010
- Publication type:
- Opinion
10
Modafinil for the treatment of multiple sclerosis-related fatigue.
- Published in:
- 2010
- Publication type:
- Opinion
11
Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry.
- Published in:
- 2010
- Publication type:
- Opinion
12
UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production.
- Published in:
- 2010
- Publication type:
- Opinion
13
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week Phase II trial.
- Published in:
- 2010
- Publication type:
- Opinion
14
Daclizumab in active relapsing multiple sclerosis (CHOI CE study): a Phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta.
- Published in:
- 2010
- Publication type:
- Opinion
15
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
- Published in:
- 2010
- Publication type:
- Opinion
16
[1] Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS./[2] Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
- Published in:
- 2010
- Publication type:
- Opinion
17
Laquinimod, a new oral autoimmune modulator for the treatment of relapsingremitting multiple sclerosis.
- Published in:
- 2010
- Publication type:
- Opinion
18
Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service.
- Published in:
- 2010
- Publication type:
- Opinion
19
Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
- Published in:
- 2010
- Publication type:
- Opinion
20
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
- Published in:
- 2010
- Publication type:
- Opinion
21
Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
- Published in:
- 2010
- Publication type:
- Opinion
22
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsingremitting Multiple Sclerosis (ASIIMS) trial.
- Published in:
- 2010
- Publication type:
- Opinion
23
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
- Published in:
- 2010
- Publication type:
- Opinion
24
Escalating Immunotherapies for Highly Active Multiple Sclerosis: Reviewing the Evidence.
- Published in:
- Current Medical Literature: Multiple Sclerosis, 2010, v. 2, n. 3, p. 61
- By:
- Publication type:
- Article
25
Foreword.
- Published in:
- Current Medical Literature: Multiple Sclerosis, 2010, v. 2, n. 3, p. 61
- By:
- Publication type:
- Article